SG11202112354SA - Crystal form of pyridone derivative, and preparation method and use thereof - Google Patents
Crystal form of pyridone derivative, and preparation method and use thereofInfo
- Publication number
- SG11202112354SA SG11202112354SA SG11202112354SA SG11202112354SA SG11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- crystal form
- pyridone derivative
- pyridone
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910381020.0A CN111909174B (en) | 2019-05-08 | 2019-05-08 | Crystal form of pyridone derivative, preparation method and application |
| PCT/CN2019/115641 WO2020224208A1 (en) | 2019-05-08 | 2019-11-05 | Pyridone derivative crystal form and preparation method and application therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112354SA true SG11202112354SA (en) | 2021-12-30 |
Family
ID=73050743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112354SA SG11202112354SA (en) | 2019-05-08 | 2019-11-05 | Crystal form of pyridone derivative, and preparation method and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230144122A1 (en) |
| EP (1) | EP3967697A4 (en) |
| CN (2) | CN111909174B (en) |
| AU (1) | AU2019444375B2 (en) |
| CA (1) | CA3139343A1 (en) |
| SG (1) | SG11202112354SA (en) |
| WO (1) | WO2020224208A1 (en) |
| ZA (1) | ZA202108765B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022247759A1 (en) * | 2021-05-22 | 2022-12-01 | 江西彩石医药科技有限公司 | Intermediate of pyridone derivative and preparation method therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2444400T (en) * | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoylpyridone derivative |
| TR201810736T4 (en) * | 2010-09-24 | 2018-08-27 | Shionogi & Co | Substituted polycyclic carbamoyl pyridone derivative prodrug. |
| EP4219508B1 (en) * | 2015-04-28 | 2024-06-05 | Shionogi & Co., Ltd | Substituted polycyclic pyridone derivative and prodrug thereof |
| CN110494141A (en) * | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | Pharmaceutical composition containing substituted polycyclic Pyridione derivatives and its prodrug |
| KR102477187B1 (en) * | 2018-01-17 | 2022-12-12 | 장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드 | Pyridone derivatives, their stereoisomers and their applications as anti-influenza virus drugs |
-
2019
- 2019-05-08 CN CN201910381020.0A patent/CN111909174B/en active Active
- 2019-11-05 AU AU2019444375A patent/AU2019444375B2/en active Active
- 2019-11-05 WO PCT/CN2019/115641 patent/WO2020224208A1/en unknown
- 2019-11-05 SG SG11202112354SA patent/SG11202112354SA/en unknown
- 2019-11-05 EP EP19928278.1A patent/EP3967697A4/en active Pending
- 2019-11-05 CN CN201980005140.9A patent/CN111670191B/en active Active
- 2019-11-05 CA CA3139343A patent/CA3139343A1/en active Pending
- 2019-11-05 US US17/595,013 patent/US20230144122A1/en active Pending
-
2021
- 2021-11-08 ZA ZA2021/08765A patent/ZA202108765B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019444375B2 (en) | 2023-04-20 |
| EP3967697A4 (en) | 2023-07-05 |
| CN111670191A (en) | 2020-09-15 |
| CN111670191B (en) | 2021-07-13 |
| ZA202108765B (en) | 2023-07-26 |
| CN111909174B (en) | 2022-01-21 |
| CA3139343A1 (en) | 2020-11-12 |
| AU2019444375A1 (en) | 2021-12-02 |
| CN111909174A (en) | 2020-11-10 |
| WO2020224208A1 (en) | 2020-11-12 |
| EP3967697A1 (en) | 2022-03-16 |
| US20230144122A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291467A (en) | Fused pyridone compound, and preparation method therefor and use thereof | |
| EP3470400A4 (en) | Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor | |
| EP3287444A4 (en) | New crystal form of lenvatinib methanesulfonate salt and preparation method thereof | |
| EP3682884A4 (en) | Crystal form of gsk1278863 and preparation method and pharmaceutical use thereof | |
| EP3632907A4 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| EP3508481A4 (en) | Crystal form of ozanimod hydrochloride, and preparation method therefor | |
| EP3812378A4 (en) | Crystal form of arn-509, preparation method therefor and use thereof | |
| IL283968A (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| EP3647312A4 (en) | Crystal form of deuterated azd9291, preparation method therefor, and use thereof | |
| EP4059926A4 (en) | Crystal form of tafamidis and preparation method therefor and use thereof | |
| EP3502103A4 (en) | Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor | |
| EP3530650A4 (en) | Crystalline form of (r)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof | |
| EP3677575A4 (en) | Crystalline form of ozanimod hydrochloride and preparation method therefor | |
| EP3658278A4 (en) | Crystalline metallophosphates, their method of preparation, and use | |
| EP3569590A4 (en) | (r)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof | |
| EP3466939A4 (en) | New dapagliflozin crystal form and preparation method and use thereof | |
| EP3712155A4 (en) | Crystal form of sesquiterpene derivative, preparation method therefor and use thereof | |
| EP3696168A4 (en) | Method for preparation of 2-chloro-5-trifluoromethylpyridine | |
| EP3272751A4 (en) | Crystal form of ipi-145 and preparation method thereof | |
| EP3572399A4 (en) | Crystal form of gft-505 and preparation method and use thereof | |
| EP4073049A4 (en) | Novel crystalline forms of flufenacet, methods for their preparation and use of the same | |
| EP3545957A4 (en) | Pyridone derivative pharmaceutical composition and preparation method thereof | |
| SG11202112354SA (en) | Crystal form of pyridone derivative, and preparation method and use thereof | |
| EP3733666A4 (en) | Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof | |
| EP3741746A4 (en) | Crystal form of oxopicolinamide derivative and preparation method therefor |